Articles

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-...

Export this record

Export selected records

Export record to excel

File type to download

Beta version

Record title

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Record identifier

TN_cdi_hal_primary_oai_HAL_hal_01868690v1

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

ACCESS
https://collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01868690v1

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Full title

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2016, Vol.17 (6), p.822-835

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_01868690v1

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

SCOPE AND CONTENTS

Contents

Summary Background Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed to assess the efficacy of the MAGE-A3 cancer immunotherapeutic in surgically resected NSCLC. Methods...

ALTERNATIVE TITLES

Full title

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Identifiers

PRIMARY IDENTIFIERS

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_01868690v1

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01868690v1

OTHER IDENTIFIERS

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(16)00099-1

How to access this item

Online

1 item

How to access?

Login with a Library card